MedGenome appoints Dr Amit Kakar as Chairman of its Board

Dr Kakar takes over from Dr Felix Olale

MedGenome has announced the appointment of Dr Amit Kakar as Chairman of its Board, effective immediately.

Dr Kakar takes over from Dr Felix Olale, who concluded his two-year term as Chairman of the Board and will focus his efforts on leading the growth of MedGenome's US and North America business. 

Dr Kakar has served on the MedGenome board of directors since 2022 and is Managing Partner and Head of Asia at Novo Holdings, a global life sciences investor wholly owned by the Novo Nordisk Foundation, an independent philanthropic enterprise foundation. He has over 30 years of experience in the Healthcare and Life Sciences industry and serves on the boards of Doctor Anywhere, an omnichannel healthcare service provider; ESCO, a Singapore-based life science company; and Qure.ai, a leading health tech firm headquartered in India.

"I am honoured to be serving as Chairman at an exciting time for the company. MedGenome has been at the forefront of revolutionising healthcare through its deep technology and innovation capabilities in the field of genomics. I look forward to working closely with the board and management team as we continue to play our part in making healthcare solutions affordable and accessible for all. Together with the talented team at MedGenome, we will work towards expanding our reach and ensuring that our solutions can make a difference in the lives of people across the globe," said Dr Kakar.

Dr Kakar previously served as the Head of Healthcare Investments at Avenue Capital for eight years where he was responsible for the company's pan-Asia healthcare investments. He was also part of GE Healthcare for over 14 years, holding various senior positions in India, China, and the US; and was Head of M&A and Business Development at Everlife Asia in Singapore.

With a distinguished career spanning over three decades of healthcare investing, operations, management and leadership, his commitment to excellence, coupled with a deep understanding of the markets, will provide strong strategic direction to MedGenome's next phase of growth in the coming years.

Mahesh Pratapneni, Group CEO & Co-founder of MedGenome said, "Dr Kakar has played a pivotal role in guiding the company to accomplish its organic and inorganic expansion plans. In his new role as Chairman of the Board, Dr Kakar will continue to guide the company on its growth initiatives. His sector expertise, leadership experience, strong industry connections, and deep knowledge of our business are powerful assets to both the board and the company as we execute our long-term strategy."